Therapeutic role of interleukin 22 in experimental intra-abdominal Klebsiella pneumoniae infection in mice

Infection and Immunity

Volumn 84, Issue 3, 2016, Pages 782-789

  Zheng, Mingquan ^a   Horne, William ^a   McAleer, Jeremy P ^a   Pociask, Derek ^b   Eddens, Taylor ^a,c   Good, Misty ^a   Gao, Bin ^d   Kolls, Jay K ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; INTERLEUKIN 22 RECEPTOR ALPHA 1; INTERLEUKIN RECEPTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 22; STAT3 PROTEIN; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; INTERLEUKIN-22 RECEPTOR;

ABDOMINAL INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERIOSTASIS; CFU COUNTING; GENE OVEREXPRESSION; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; LIVER INJURY; LIVER NECROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; FEMALE; GENETICS; HUMAN; INTRAABDOMINAL INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; KNOCKOUT MOUSE; MALE; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; FEMALE; HUMANS; INTERLEUKINS; INTRAABDOMINAL INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN; STAT3 TRANSCRIPTION FACTOR;

EID: 84962145363     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01268-15     Document Type: Article

References (34)

1. James J, Liou IW. 2015. Comprehensive care of patients with chronic liver disease. Med Clin North Am 99:913-933. http://dx.doi.org/10.1016/j.mcna.2015.05.001.
2. Dever JB, Sheikh MY. 2015. Review article: spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther 41:1116-1131. http://dx.doi.org/10.1111/apt.13172.
3. Jha AK, Nijhawan S, Suchismita A. 2011. Sepsis in acute on chronic liver failure. Dig Dis Sci 56:1245-1246, author reply 1246. http://dx.doi.org/10.1007/s10620-011-1605-2.
4. Kim TY, Kim DJ. 2013. Acute-on-chronic liver failure. Clin Mol Hepatol 19:349-359. http://dx.doi.org/10.3350/cmh.2013.19.4.349.
5. Aujla SJ, Kolls JK. 2009. IL-22: a critical mediator in mucosal host defense. J Mol Med (Berl) 87:451-454. http://dx.doi.org/10.1007/s00109-009-0448-1.
6. Spits H, Cupedo T. 2012. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 30:647-675. http://dx.doi.org/10.1146/annurev-immunol-020711-075053.
7. Lecart S, Morel F, Noraz N, Pene J, Garcia M, Boniface K, Lecron JC, Yssel H. 2002. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 14:1351-1356. http://dx.doi.org/10.1093/intimm/dxf096.
8. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. 2004. IL-22 increases the innate immunity of tissues. Immunity 21:241-254. http://dx.doi.org/10.1016/j.immuni.2004.07.007.
9. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. 2002. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10 J Biol Chem 277:33676-33682.
10. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14:275-281. http://dx.doi.org/10.1038/nm1710.
11. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, Ouyang W. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14:282-289. http://dx.doi.org/10.1038/nm1720.
12. Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA, Kunisawa J, Shibata N, Grunberg S, Sinha R, Zahm AM, Tardif MR, Sathaliyawala T, Kubota M, Farber DL, Collman RG, Shaked A, Fouser LA, Weiner DB, Tessier PA, Friedman JR, Kiyono H, Bushman FD, Chang KM, Artis D. 2012. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336: 1321-1325. http://dx.doi.org/10.1126/science.1222551.
13. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. 2007. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27:647-659. http://dx.doi.org/10.1016/j.immuni.2007.07.023.
14. Xing WW, Zou MJ, Liu S, Xu T, Wang JX, Xu DG. 2011. Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci Biotechnol Biochem 75:1290-1294. http://dx.doi.org/10.1271/bbb.110061.
15. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, Gao B. 2010. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 52:1291-1300. http://dx.doi.org/10.1002/hep.23837.
16. Garbers C, Aparicio-Siegmund S, Rose-John S. 2015. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol 34:75-82. http://dx.doi.org/10.1016/j.coi.2015.02.008.
17. Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, Ki SH, Yoo SH, Dooley S, Wang FS, Young HA, Gao B. 2011. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 54:252-261. http://dx.doi.org/10.1002/hep.24339.
18. Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, Mak TW, Clifton MC, Strong RK, Ray P, Kolls JK. 2009. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J Immunol 182:4947-4956. http://dx.doi.org/10.4049/jimmunol.0803282.
19. Ray M, Horne W, McAleer JP, Ricks DM, Kreindler JL, Fitzsimons MS, Chan PP, Trevejo-Nunez G, Chen K, Fajt M, Chen W, Ray A, Wenzel S, Kolls JK. 2015. RNA-seq in Pulmonary Medicine: How Much Is Enough? Am J Respir Crit Care Med 192:389-391. http://dx.doi.org/10.1164/rccm.201403-0475LE.
20. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. 2010. Biology of interleukin-22. Semin Immunopathol 32:17-31. http://dx.doi.org/10.1007/s00281-009-0188-x.
21. Kong X, Feng D, Mathews S, Gao B. 2013. Hepatoprotective and antifibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol 28(Suppl 1:S56-S60.
22. Xu MJ, Feng D, Wu H, Wang H, Chan Y, Kolls J, Borregaard N, Porse B, Berger T, Mak TW, Cowland JB, Kong X, Gao B. 2015. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology 61:692-702. http://dx.doi.org/10.1002/hep.27447.
23. Zhang B, Chassaing B, Shi Z, Uchiyama R, Zhang Z, Denning TL, Crawford SE, Pruijssers AJ, Iskarpatyoti JA, Estes MK, Dermody TS, Ouyang W, Williams IR, Vijay-Kumar M, Gewirtz AT. 2014. Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. Science 346:861-865. http://dx.doi.org/10.1126/science.1256999.
24. Sonnenberg GF, Fouser LA, Artis D. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12:383-390. http://dx.doi.org/10.1038/ni.2025.
25. Choi SM, McAleer JP, Zheng M, Pociask DA, Kaplan MH, Qin S, Reinhart TA, Kolls JK. 2013. Innate Stat3-mediated induction of the antimicrobial protein Reg3gamma is required for host defense against MRSA pneumonia. J Exp Med 210:551-561. http://dx.doi.org/10.1084/jem.20120260.
26. Pickard JM, Maurice CF, Kinnebrew MA, Abt MC, Schenten D, Golovkina TV, Bogatyrev SR, Ismagilov RF, Pamer EG, Turnbaugh PJ, Chervonsky AV. 2014. Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 514:638-641. http://dx.doi.org/10.1038/nature13823.
27. Pham TA, Clare S, Goulding D, Arasteh JM, Stares MD, Browne HP, Keane JA, Page AJ, Kumasaka N, Kane L, Mottram L, Harcourt K, Hale C, Arends MJ, Gaffney DJ, Dougan G, Lawley TD. 2014. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe 16:504-516. http://dx.doi.org/10.1111/cmi.12232,http://dx.doi.org/10.1016/j.chom.2014.08.017.
28. Goto Y, Obata T, Kunisawa J, Sato S, Ivanov II, Lamichhane A, Takeyama N, Kamioka M, Sakamoto M, Matsuki T, Setoyama H, Imaoka A, Uematsu S, Akira S, Domino SE, Kulig P, Becher B, Renauld JC, Sasakawa C, Umesaki Y, Benno Y, Kiyono H. 2014. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science 345:1254009. http://dx.doi.org/10.1126/science.1254009.
29. Radaeva S, Sun R, Pan HN, Hong F, Gao B. 2004. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39:1332-1342 http://dx.doi.org/10.1002/hep.20184.
30. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, Gao B. 2012. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 56:1150-1159. http://dx.doi.org/10.1002/hep.25744.
31. Sertorio M, Hou X, Carmo RF, Dessein H, Cabantous S, Abdelwahed M, Romano A, Albuquerque F, Vasconcelos L, Carmo T, Li J, Varoquaux A, Arnaud V, Oliveira P, Hamdoun A, He H, Adbelmaboud S, Mergani A, Zhou J, Monis A, Pereira LB, Halfon P, Bourliere M, Parana R, Dos Reis M, Gonnelli D, Moura P, Elwali NE, Argiro L, Li Y, Dessein A. 2015. IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology 61: 1321-1331. http://dx.doi.org/10.1002/hep.27629.
32. Bachman MA, Oyler JE, Burns SH, Caza M, Lepine F, Dozois CM, Weiser JN. 2011. Klebsiella pneumoniae yersiniabactin promotes respiratory tract infection through evasion of lipocalin 2. Infect Immun 79: 3309-3316. http://dx.doi.org/10.1128/IAI.05114-11.
33. Du Clos TW. 2013. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm 2013:379040. http://dx.doi.org/10.1155/2013/379040.
34. Liu C, Cripe TP, Kim MO. 2010. Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. Mol Ther 18:1724-1730. http://dx.doi.org/10.1038/mt.2010.127.